Background: Emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. Current method of detection involves qPCR-based technique, which identifies the viral nucleic acids when present in sufficient quantity. False negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission. We here aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus (SARS-CoV-2) and evaluate the potential of antibody testing to diagnose COVID-19.
Methods: The host humoral response against SARS-CoV-2 including IgA, IgM and IgG response were examined by using an ELISA based assay on the recombinant viral nucleocapsid protein. Total 208 plasma samples were collected from 82 confirmed and 58 probable cases (qPCR negative but had typical manifestation). The diagnostic value of IgM was evaluated in this cohort.
Results: The median duration of IgM and IgA antibody detection were 5 days (IQR 3-6), while IgG was detected on 14 days (IQR 10-18) after symptom onset, with a positive rate of 85.4%, 92.7% and 77.9% respectively. In confirmed and probable cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively. The detection efficiency by IgM ELISA is higher than that of qPCR method after 5.5 days of symptom onset. The positive detection rate is significantly increased (98.6%) when combined IgM ELISA assay with PCR for each patient compare with a single qPCR test (51.9%).
Conclusions: Humoral response to SARS-CoV-2 can aid to the diagnosis of COVID-19, including subclinical cases.
Keywords: COVID-19; ELISA; antibody; diagnosis; novel coronavirus.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: firstname.lastname@example.org.
Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus.Clin Diagn Lab Immunol. 2004 Jul;11(4):665-8. doi: 10.1128/CDLI.11.4.665-668.2004. Clin Diagn Lab Immunol. 2004. PMID: 15242938 Free PMC article.
Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2.J Clin Microbiol. 2020 Mar 30:JCM.00461-20. doi: 10.1128/JCM.00461-20. Online ahead of print. J Clin Microbiol. 2020. PMID: 32229605
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.Lancet Infect Dis. 2020 Mar 23:S1473-3099(20)30196-1. doi: 10.1016/S1473-3099(20)30196-1. Online ahead of print. Lancet Infect Dis. 2020. PMID: 32213337
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.J Microbiol Immunol Infect. 2020 Mar 4:S1684-1182(20)30040-2. doi: 10.1016/j.jmii.2020.02.012. Online ahead of print. J Microbiol Immunol Infect. 2020. PMID: 32173241 Review.
The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.J Med Virol. 2020 Feb 27. doi: 10.1002/jmv.25728. Online ahead of print. J Med Virol. 2020. PMID: 32104915 Review.